This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB04934/identifier/pubchem-substance/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04934/identifier/kegg-drug/
n6http://linked.opendata.cz/resource/drugbank/drug/DB04934/identifier/drugbank/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB04934/identifier/pubchem-compound/

Statements

Subject Item
n2:DB04934
rdf:type
n3:Drug
n3:description
Benzoxazinorifamycin (trade name rifalazil) is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.
n3:generalReferences
# Mae T, Inaba T, Konishi E, Hosoe K, Hidaka T: Identification of enzymes responsible for rifalazil metabolism in human liver microsomes. Xenobiotica. 2000 Jun;30(6):565-74. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10923859 # Rothstein DM, Hartman AD, Cynamon MH, Eisenstein BI: Development potential of rifalazil. Expert Opin Investig Drugs. 2003 Feb;12(2):255-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12556219
n3:group
investigational
n3:indication
Investigated for use/treatment in atherosclerosis, bacterial infection, and peripheral vascular disease.
owl:sameAs
n11:DB04934
dcterms:title
Benzoxazinorifamycin
adms:identifier
n6:DB04934 n7:17396721 n8:D02550 n9:6540558
n3:mechanismOfAction
The potent antimycobacterial activity of benzoxazinorifamycin is due to inhibition of bacterial RNA polymerase.
n3:synonym
RLZ KRM-1648
n3:IUPAC-Name
n4:271B5FE2-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5FE8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5FE7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5FE4-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5FE5-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5FE6-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5FE0-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5FE1-363D-11E5-9242-09173F13E4C5 n4:271B5FDE-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5FDF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5FEE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5FEF-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5FE9-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5FEA-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5FEC-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5FEB-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5FED-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Bacteria
n3:casRegistryNumber
129791-92-0
n3:category
n3:Bioavailability
n4:271B5FF4-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5FF6-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5FF7-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5FF3-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5FF2-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5FF5-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5FE3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5FF0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5FF1-363D-11E5-9242-09173F13E4C5